ELVN — Enliven Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology
$61.01
-$0.14 (-0.23%)
Enliven Therapeutics Inc. (ELVN) is a biotechnology company listed on NASDAQ. It is led by Richard A. Fair M.B.A., based in 6200 Lookout Road, Boulder, CO, United States, 80301, with about 61 employees. Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Net income was -$20.1M. ELVN currently screens at market cap $2.11B.
Use this ELVN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ELVN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ELVN SEC filings page. Lician reads the product cache first so this HTML stays unique to Enliven Therapeutics Inc. even when a live quote feed is slow.
About Enliven Therapeutics Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
ELVN Key Statistics
Market Cap
$2.11B
Volume
804,221
Previous Close
$61.15
Day Range
$60.57 – $62.00
EPS
-$1.89
Revenue
$0.00
Net Income
-$89.02M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
61
ELVN Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$89.02M | -$71.58M | -$37.66M | -$51.38M |
| EPS (Diluted) | -$1.89 | -$2.01 | -$12.05 | -$2.37 |
Total Assets
$325.76M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$124.12M
Operating Cash Flow
-$73.19M
Free Cash Flow
$0.00
Enliven Therapeutics Inc. Company Information
- CEO, President & Director
- Richard A. Fair M.B.A.
- Headquarters
- 6200 Lookout Road, Boulder, CO, United States, 80301
- Website
- www.enliventherapeutics.com
- Phone
- 720 647 8519
- IPO / Founded
- 2020-03-12
- Sector
- Healthcare
- Industry
- Biotechnology